CompletedPhase 4

POST-CABGDM: Empagliflozin in Perioperative CABG

Brazil155 participantsStarted 2020-09-22

Plain-language summary

Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surgery is commonly indicated to patients with multivessel coronary disease and kidney injury is a prevalent complication in post operation. This work aims to evaluate the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with cardiopulmonary bypass

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \> 18 * Type 2 diabetes mellitus * Multivessel CAD documented by coronary angiography with formal indication for CRM. Exclusion Criteria: * eGFR \<30mL / min / 1.73m2 or dialysis therapy; * Inability to sign the informed consent form; * Contraindication to CABG on pump; * Need for urgent or emergency CABG; * Terminal or disabling illness with reduced life expectancy; * Pregnancy in progress.

What they're measuring

Acute kidney injury

Timeframe: 3 months

Trial details

NCT IDNCT04523064

SponsorUniversity of Sao Paulo General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-30

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials